Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in CRSP.
← Back to Free Index

CRSP

Analysis as of: 2026-05-14
CRISPR Therapeutics AG
CRISPR Therapeutics develops gene-edited medicines, co-commercializes CASGEVY with Vertex, and advances wholly owned in vivo editing, cell therapy, siRNA, and regenerative medicine programs.
biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Second-franchise proof drives the rerating case
One approved product and a deep cash runway buy time, but the real five-year upside depends on turning platform breadth into one more genuine franchise. If owned-program data work, the market can stop valuing the story as cash plus optionality.

Analysis

Thesis
CRISPR Therapeutics can move from a one-product proof story to a two-engine editing company if CASGEVY keeps scaling and one owned franchise, most likely liver editing or zugo-cel, crosses into clear commercial relevance by 2031.
Last Economy Alignment
AI helps target selection, design, and portfolio speed, but value capture here sits in regulated human data, IP, manufacturing, and clinical trust. That is a real advantage, yet biology and approvals remain the binding constraints.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.9x (from 5 most recent analyses)
Reasoning
The rerating does not require every program to work. It requires CASGEVY to become a durable profit stream, one owned program to produce convincing efficacy and scalable economics, and the company to keep enough downstream rights that scientific success turns into shareholder value. If that happens, the market can revalue the business from platform optionality to a de-risked multi-franchise editor.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is proof conversion beyond CASGEVY. CRISPR Therapeutics has enough capital and technical credibility to stay in the game, but the 2031 upside still depends on showing that at least one owned program can clear clinical, regulatory, manufacturing, and economic hurdles well enough to become a real franchise rather than a perpetual platform promise.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.44
AI can help them design and prioritize edits faster, but the real value is in things that are hard to copy: human data, regulatory trust, and manufacturing control. That gives them upside, though biology and approvals still slow the flywheel.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$64.82
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case